Thu, Sep 18, 2014, 4:50 AM EDT - U.S. Markets open in 4 hrs 40 mins

Recent

% | $
Quotes you view appear here for quick access.

Bergamo Acquisition Corp. Message Board

  • assetmanagement65 assetmanagement65 Jun 28, 2013 12:49 PM Flag

    VistaGen Provides Update on $36 Million Strategic Financing Agreement

    SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/28/13

    VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.

    Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.

    Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

    About VistaGen Therapeutics

    VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube?, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical or biotechnology companies,

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.

      Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.

      Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

      Sentiment: Strong Buy

      • 3 Replies to undervalued95
      • Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs

        SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 10, 2013) - VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (PINKSHEETS: BGMO), a global diversified investment holding company.

        Under the terms of the agreement, Bergamo's European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share. The Company's self-placed strategic financing does not include warrants or any investment banking fees. The transaction is scheduled to close on or before April 30, 2013. At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen's Common Stock.

        VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe™ 3D and LiverSafe™ 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube™ platform.

        "Since our

        Sentiment: Strong Buy

      • June 29 2013 Vistagen Therapeutics (USOTC:VSTA) FINANCING UPDATE

        VistaGen Provides Update on $36 Million Strategic Financing Agreement

        VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.

        Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.

        Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

        Sentiment: Strong Buy

      • VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.
        Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.

        Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."

        Sentiment: Strong Buy

    • scam

      Sentiment: Strong Sell

      • 4 Replies to camino482000
      • VSTA & Their Top Notch Service Provider's, Including 10 Board Members who are Highly Qualified,

        Sentiment: Strong Buy

      • VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.

        Sentiment: Strong Buy

      • Autillion AG sounds like billionaires Deposits are secured in Swiss Bank accounts.

        It's not a matter of if BGMO will acquire approximately 70% of VSTA it just a matter of when.

        We know the hold period of the of the initial profit of $88 million earned from the first tranche of investment funds of US $500 million will be up in a couple of months, but obviously BGMO and VSTA management believe the acquisition of VSTA will happen before then.

        Quote:
        In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada

        Timing is everything

        FACTS !!!!

        Sentiment: Strong Buy

      • VistaGen Therapeutics Board of Directors APPROVED RECENT TRANSACTION

        Jon S. Saxe,
        Chairman

        Brian J. Underdown, Ph.D.,
        Director

        H. Ralph Snodgrass, Ph.D.,
        Founder, President and Chief Scientific Officer

        Shawn K. Singh, J.D.
        Chief Executive Officer

        Management Team

        Shawn K. Singh, J.D.
        Chief Executive Officer, Director

        H. Ralph Snodgrass, Ph.D.
        Founder, President and Chief Scientific Officer, Director

        Jerrold D. Dotson, CPA
        Acting Chief Financial Officer

        A. Franklin Rice, MBA
        VP of Corporate Development, Secretary

        Scientific Advisory Board

        Gordon Keller, Ph.D.
        Chairman, Director, McEwen Centre for Regenerative Medicine, University Health Network
        DIRECTOR'S OF VSTA APPROVED RECENT TRANSACTION LIKE IT OR NOT

        Peter Backx, D.V.M., Ph.D.
        Professor, University of Toronto, Departments of Physiology and Medicine

        George Clay, Ph.D.
        Chief Operating Officer (retired), Kyowa Pharmaceuticals

        Arthur Fetter, D.V.M., Ph.D.
        Sr. Vice President (retired), Worldwide Drug Safety, Rhone-Poulenc Rorer

        Jack Gauldie, Ph.D.
        Director, Centre for Gene Therapeutics, McMaster University

        John Lowe, Ph.D.
        Senior Research Fellow (retired), Medicinal Chemistry and Drug Discovery, Pfizer Global R&D

        James E. Sanders, D.V.M., Ph.D.
        Senior Director and Preclinical Development Leader (retired), Johnson & Johnson

        Ron Wester, Ph.D. Vice President (retired)
        Medicinal Chemistry and Drug Discovery, Pfizer Global R&D

        Sentiment: Strong Buy

    • SOUTH SAN FRANCISCO, CA, Jun 17, 2013 (Marketwired via COMTEX) -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, presented key developments involving its CardioSafe 3D(TM) and LiverSafe 3D(TM) bioassay systems in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), the largest forum for stem cell and regenerative medicine professionals from around the world, held June 12 to 15, 2013, in Boston, Massachusetts.
      Dr. Hai-Qing Xian, Senior Scientist, presented VistaGen's poster entitled "Cardiotoxicity Assessment of Anti-Cancer Kinase Inhibitors using Human Pluripotent Stem Cell-Derived Cardiomyocyte Based Assays," which detailed important developments demonstrating that CardioSafe 3D(TM), VistaGen's high throughput, human heart cell-based bioassay, is a clinically predictive system for preclinical cardiac safety screening of anti-cancer drug candidates, including small molecule kinase inhibitors (KIs), a new category of drugs that have revolutionized cancer therapy due to decreased systemic toxicity and increased target cell efficacy compared to classic cancer drugs, as well as other therapeutic compounds. VistaGen demonstrated the utility of CardioSafe 3D(TM) to detect cardiac toxicities of well-known anti-cancer KIs, including imatinib, dasatinib, sunitinib, erlotinib and temsirolimus, which have been associated with adverse clinical cardiac events that were not detected during the drug development process. As demonstrated in the poster presentation, CardioSafe 3D(TM) successfully detected cardiotoxicity induced by representative compounds from different KI categories. Additionally, the bioassay system provided clues to the major mechanisms of cardiac cytotoxicity induced by each compound, thus enabling not only the identification of toxicities early in the drug development process, but also discove

      Sentiment: Strong Buy

      • 5 Replies to assetmanagement65
      • VSTA to Address U.S. Pharmaceutical “Crisis” with Innovative Stem Cell-based Technology

        Since its inception in 1998, the U.S. National Institutes of Health (NIH) has awarded biotech small-cap VistaGen Therapeutics with $11.3 million in R&D grants, including $2.3 million to support the company’s development of its Human Clinical Trials in a Test Tube™ platform, and $8.8 million for nonclinical and phase 1 clinical development of AV-101, the company’s lead small molecule drug candidate.

        The company has also been awarded approximately $1.0 million of grant funding from the California Institute for Regenerative Medicine (CIRM) pertaining to R&D related to liver cells.

        VSTA’s corporate development strategy hinges on strategic collaborations, which provides the company valuable access to cutting-edge expertise at a lower price than it would cost to develop the expertise internally. Ideal third-party collaborators include academic research institutions for stem cell research; CROs, which offer regulatory and drug development expertise; and medicinal chemistry companies that analyze drug rescue candidates and generate drug rescue variants.

        Sentiment: Strong Buy

      • Shawn K. Singh, J.D., Chief Executive Officer, Director

        Mr. Singh has over 20 years of experience working with successful public and private biotechnology and pharmaceutical companies, a life sciences venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining us as Chief Executive Officer in August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research, a global, full-service CRO for which he served as Chief Business Officer. Mr. Singh also served as President and Director of Echo Therapeutics (NASDAQ: ECTE), a medical device company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in hospital critical care units and for people with diabetes, and as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases, and cardiovascular, urological, respiratory, and central nervous system disorders. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, an international law firm. He is a member of the State Bar of California.

        Sentiment: Strong Buy

      • VistaGen Provides Update on $36 Million Strategic Financing Agreement
        Ticker Symbol: U:VSTA

        SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/28/13

        VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.

        Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.

        Sentiment: Strong Buy

      • VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.

        Sentiment: Strong Buy

      • VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe(TM) 3D and LiverSafe(TM) 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube(TM) platform.

        Sentiment: Strong Buy

 
BGMO
0.0050.000(0.00%)Sep 8 11:29 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.